Dr. Lesser on Armodafinil for Radiation-Induced Fatigue
Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for radiation-induced fatigue in patients with brain tumors.
Fortunately, Lesser says, researchers were able to look at a variety of endpoints in the phase II double-blind placebo-controlled study. Sleepiness, time spent sleeping, and other quality of life metrics standardized in the field were analyzed.
In the study, the group as a whole did not seem to benefit from armodafinil. However, the half of the population with lower initial quality of life scores did see a marked, statistically significant benefit when armodafinil was added to radiation therapy.